Orion Oyj Series B

Orion and its subsidiaries develop and manufacture pharmaceuticals, active pharmaceutical ingredients and diagnostic tests that are marketed globally. Co. and its subsidiaries have two segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals business develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients. The Pharmaceuticals business portfolio includes Co.'s Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs. The Diagnostics business develops, manufactures and markets diagnostic tests.
  • TickerORNBV
  • ISINFI0009014377
  • ExchangeNasdaq Nordic Helsinki
  • SectorPharmaceuticals & Biotechnology
  • CountryFinland
Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad in the eyes of the market. While we view the fact that none of these issues have yet to derail global m...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Lower High Forming? Major global indexes are showing waning upside momentum and we believe near-term consolidation is likely. This is supported by the charts and the idea that consolidation makes sense following the massive gains off of the March lows. We also believe that the market is in a “wait-and-see” phase as it relates to states and countries re-opening. A resolution of this consolidation period above resistance (bullish) or below support (bearish) will tell us where the major global averages are headed next. · Wedge/Uptrend Breakdowns. Last week we highlighted potential resis...

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior